June 12, 2023
Astellas Pharma said on June 9 that it filed a new drug application (NDA) in Japan on the same day for its Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody zolbetuximab. Zolbetuximab was submitted for the first-line treatment of patients with locally advanced...read more